BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy

Reuters01-28
BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy

** Shares of Immix Biopharma IMMX.O rise 4.4% to $6.20 premarket

** Co says the U.S. FDA has granted a 'breakthrough therapy' designation to NXC-201 for the treatment of AL Amyloidosis, a type of blood disorder

** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** Says the tag is based on mid-stage trial results of NXC-201

** Co plans to submit marketing application for the therapy this year

** AL amyloidosis is a rare and serious blood-related disorder where abnormal proteins build up in vital organs, interfering with their function

** As of last close, stock has more than tripled in the last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment